Brutalist Biotech

• Moderna withdraws FDA filing for flu/COVID combination vaccine, plans resubmission with efficacy data (1h)
• Roche's Genentech sticks with Orionis in 2nd molecular glue deal worth $2B (2h)
• Accropeutics' TYK2/JAK1 inhibitor hits psoriasis endpoints in Chinese biotech's first phase 2 win (5h)
• PureTech shows durability of pulmonary fibrosis candidate deupirfenidone (20h)
• Schrödinger lays off 60 staffers amid ‘uncertain times and challenging economic conditions’ (22h)

• FDA sets stricter approval standards for COVID vaccines (22h)
• Tourmaline shares fall on Phase 2 data; Schrödinger cuts staff (23h)
• Pfizer buys into PD-1/VEGF competition with 3SBio deal (1d)
• Prime Medicine claims ‘proof of concept,’ but lays off staff in pivot (2d)
• Novavax’s COVID vaccine gets FDA approval, but with limits (2d)

• Researchers reveal mixed results from vaccine for cocaine addiction (43m)
• Shutting down a dementia care startup (46m)
• Genentech expands partnership with molecular glue biotech Orionis (3h)
• How PureTech’s lung fibrosis drug stacks up against the competition (3h)
• Altos Labs buys anti-aging startup Dorian Therapeutics (6h)

• In Biotech’s ‘Moribund’ Market, What Does It Take to Survive? (45m)
• Webinar: Are We There Yet? Surviving and Thriving in the Never-ending Biotech Downturn (1h)
• Genentech Bets Again on Orionis With Potential $2B+ in Crowded Molecular Glue Space (1h)
• RFK Claims Ignorance About HHS Research, Clinical Trial Cuts in Hearing (1h)
• Roche’s Genentech Fails to Win Adcomm Backing for Columvi Expansion (2h)

Bio IT World

• Innovative Practices Winner: Chromatography Data Management (9h)
• Regeneron Acquires 23andMe for $256 Million (1d)
• Trends from the Trenches: Data, Discovery, Politics (6d)
• Sweden's PROMISE Initiative: Bridging Research and Healthcare Through Multi-Omics (1w)
• CFDE Unites Data Enthusiasts During Hackathon before Kick-Off of Bio-IT World Conference (1w)

• Will AGI cure cancer? Author Karen Hao on OpenAI’s promises and track record (19m)
• Investors unfazed by FDA’s Covid vaccine framework (57m)
• With the U.S. gone, WHO nations will increase contributions (1h)
• We’re reading about Trump’s drug-pricing plan, a Moderna change of plans, and more (1h)
• Risk scores accurately predicted heart attacks, study finds. With CT scans, they did even better (5h)

• Valinor Discovery Launches to Simulate Drug Efficacy in Virtual Patients (2d)
• Dutch Startup CryoCloud Lands €2M to Automate Cryo-EM for Drug Discovery (2d)
• Kvantify Taps Gefion AI Supercomputer to Scale Quantum Chemistry Simulations for Drug Discovery (2d)
• Eligo Bioscience Gets $5M Grant to Advance Gene-Editing Skin Therapy Using Bacteria (2d)
• Absci Doses First Participants in Phase 1 Trial of AI-Designed Antibody for IBD (2d)

• Layoffs in the US: what is going on with genomics companies? (46m)
• Gene therapy for skin diseases: A field still finding its footing (6h)
• Seven lung cancer companies advancing new treatments in 2025 (1d)
• Will Europe become the new home for US researchers affected by policy shifts? (2d)
• Nine promising small molecule drug discovery companies to look out for in 2025 (5d)

• Potential ALS Mitochondrial Target Identified with CRISPR, scRNA-seq (2h)
• Oligo Factory’s Low-Scale Synthesis Expands Access to Small, GMP-Ready Custom Nucleotides (2h)
• Rapid Method for Cell Density Measurement Could Help Predict Tumor Response to Treatment (16h)
• ASGCT 2025: Gates Foundation “Doubling Down” on HIV Cure (1d)
• Scratch That? De Novo Antibody Design Enters the AI Drug Discovery Toolbox (1d)

• Sixteen Years With Leukemia Taught Me to Savor Life (1h)
• Finding Meaning After an Acute Myeloid Leukemia Diagnosis (17h)
• Early Arterial Thrombosis May Signal Future Cancer Risk (18h)
• What are the Long-Term Side Effects of Proton Therapy in Prostate Cancer? (19h)
• The Unnamed Nurse who Saved My Life During Breast Cancer (21h)

Contract Pharma*

• Waters Acquires Halo Labs, Expands Biologic Analysis Portfolio (15m)
• Antengene & MSD Enter into a Global Clinical Collaboration (16m)
• Regeneron in Deal to Acquire 23andMe for $256M (21h)
• Astoriom Expands Sample Stability Storage Services (22h)
• Fresenius Kabi Introduces Epinephrine Injection 30 mg per 30 mL Multi-Dose Vials (22h)

• Ionis shares phase 3 results for olezarsen in moderate hypertriglyceridaemia (3h)
• FDA approves Amneal’s self-administered migraine drug Brekiya (1d)
• MHRA approves guselkumab for Crohn’s disease and ulcerative colitis (2d)
• Massalia Therapeutics launches to advance novel treatments for complex conditions (2d)
• AviadoBio opens UK trial for FTD gene therapy (6d)

• How Healthcare Organizations Can Maintain a Balanced Workforce Amid Staff Shortages and Burnout (55m)
• A Four-Part Roadmap for Responsible Prior Authorization (1h)
• How a New PE-Backed RCM Company Plans to Fix the ‘Transactional Bowels of US Healthcare’ (10h)
• 3 Health Investors Share Their Most Controversial Industry Takes (11h)
• How a Tiny Federal Agency Supports Innovation & Competitiveness in the Scientific Community (11h)

• Editorial: Venture capital still likes cleantech (21h)
• A guide to navigating AI chemistry hype (22h)
• Federal policy changes spell turmoil for biopharma (1d)
• Global pandemic treaty nears adoption, but key obstacle remains (1d)
• ACS puts the spotlight on chemical technical professionals (2d)

The Pharma Letter*

• ReproNovo raises $65 million in Series A financing (28m)
• vTv resumes Phase III oral T1D drug study (52m)
• Protagenic Therapeutics and Phytanix merge in all stock deal (1h)
• Juvenescence raises $76 million in first-close of Series B-1 round (2h)
• SparX teams with Mitsubishi Tanabe on novel ADC project (3h)

• FDA's Project Optimus Drives Increased Dose Optimization in Early Trials (44m)
• Maintenance Selinexor Extends PFS in TP53 Wild-Type Endometrial Cancer (1h)
• CABINET Trial: Results (2h)
• CYTO-PV Trial Insights: Optimizing Hematocrit Targets and Thrombosis Prevention in Polycythemia Vera (2h)
• CABINET Trial: Study Design and Patient Population (2h)

• EU to reduce companies' administrative costs by EUR 400m (1h)
• Fruergaard's exit leaves many questions: Speculation about cause, power struggle and US problems (2h)
• US health clinic Calibrate changes management (3h)
• Demant surpasses Novo Nordisk on list of Europe's best employers (4h)
• Genmab drug gets support from US authorities (5h)

• Autoimmune Disease, Transformed? (19h)
• Lose Your Crystalline Form and Go Amorphous (1d)
• Alzheimer's Update: Infectious Agents and Gamma-Secretase Too (5d)
• Obesity Without Metabolic Dysfunction? (6d)
• New Cell Therapy For Resistant Hodgkins Patients (1w)

• US imposes limits on COVID-19 boosters and new jabs (1h)
• UK to start "world first" gonorrhoea vaccine programme (3h)
• Beckley's psychedelic med inches forward in depression (3h)
• UK trumpets £1bn investment plan from BioNTech (4h)
• First details of Trump's most favoured nation plan emerge (5h)

• In Focus report: Cell therapy and opportunities for new medicines (44m)
• BioNTech commits to up to £1 billion investment in the UK (2h)
• Weight loss with muscle preservation for novel small molecule (4h)
• Whitepaper: Transforming cardiac safety testing (5h)
• VOLTA Scanner illuminates cardiac safety testing (5h)

Google News Biotech

• In Biotech’s ‘Moribund’ Market, What Does It Take to Survive? - BioSpace (40m)
• The genomics layoff wave in the US: What is happening and why - Labiotech.eu (44m)
• Northway Biotech Enters Manufacturing Agreement With Kaida BioPharma for Lead Oncology Program KAD101 - BioSpace (45m)
• Webinar: Are We There Yet? Surviving and Thriving in the Never-ending Biotech Downturn - BioSpace (1h)
• Dividing the Equity Pie: Biotech Startup Realities with Dr. Jahanara Ali - Lexology (1h)